322 NORTH 2200 WEST, SALT LAKE CITY, UT
Separation Agreement with Brian Donnelly, Former Chief Commercial Officer
Appoints Vishal Sikri Executive Vice President - Commercial
Financial Results, Press Release
Director Resignation - Daniel M. Skovronsky Steps Down from Myriad Genetics
Myriad Genetics Approves 4 Million Share Increase in Employee Stock Purchase ...
Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report